Company intelligence / Profile preview
CompleCure
Tokyo, Japan
- Ownership
- Private
- Development stage
- Other
01
Overview
CompleCure is pioneering antibody mimetic drug conjugates (AMDC), with their most advanced program targeting breast cancer currently at the manufacturing process development stage; preclinical animal models show high anti-tumor efficacy and potential for superior safety relative to conventional therapies[2][3][4][6].
- Therapeutic areas
- Oncology
- Modalities
- Antibody mimeticAntibody-drug conjugateProteinSmall molecule
- Industry
- Biotech
02
Drug pipeline
7 assets6 more assets in the full pipeline.
Request access →03
Partnerships
AGC BiologicsUniversity of TokyoTohoku UniversityChiba University
Beyond the preview
Go deeper on CompleCure.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CompleCure.